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Article abstract-The objective of this study was to determine whether participation in clinical trials affects long-term 
outcomes in Alzheimer’s disease (AD). Participation in clinical trials for persons with dementia is often justified on the 
grounds that patients benefit from the medical oversight typical of trials, even when experimental agents do not 
demonstrate short-term benefits. This claim has not been rigorously assessed. Of 215 community-resident subjects 
enrolled in a prospective study of outcomes in AD, 101 participated in randomized clinical trials (RCTs) during the first 2 
years of follow-up. These subjects were compared with subjects who met eligibility requirements for RCTs but did not 
participate (N = 57) and with subjects who were ineligible (N  = 57), over a total of 3.5 years of follow-up. Survival 
analyses assessed risk of death, nursing home placement, and incident functional deficit end points, adjusting for baseline 
differences. Subjects who participated in RCTs were younger and more highly educated. Mortality, risk of hospitalization, 
number of medical examinations conducted by study physicians, and onset of severe functional deficit did not differ 
between the groups, but risk of nursing home admission was significantly lower among RCT participants compared with 
eligible nonparticipants and ineligible subjects (16.8% versus 36.8% and 31.6%, respectively = 0.011). The difference in 
risk of nursing home placement may represent a long-term, drug-related benefit to patients, a selection effect (caregivers 
of patients who participate in RCTs differ from caregivers of patients who do not), or a positive effect on caregivers 
(greater contact with a medical service may be associated with better care-giving outcomes). Further research is required 
to assess these effects. 
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An argument advanced for participation in clinical 
trials is that patients benefit from more intensive 
medical care even in the absence of demonstrated 
treatment effects. This claim is particularly relevant 
with Alzheimer’s disease (AD), for which therapies 
have mostly shown small benefit, and in which co- 
morbidities amenable to treatment (such as weight 
loss’ and dysphagia3) may not be recognized or ag- 
gressively treated in routine medical settings. How- 
ever, the claim of medical benefit in randomized clin- 
ical trials (RCTs) has not been rigorously assessed. 
It would be valuable to know if participation in 
clinical trials had such indirect benefits for AD pa- 
tients. First, such benefits would support more ag- 
gressive medical care for AD patients. Second, they 
may point to more generalized benefits associated 
with participation in clinical trials; for example, ef- 
fects on caregivers that enable them to care for de- 
mented patients more effectively. In this sense, the 
clinical trial itself can be considered a “treatment”; i t  
offers a package of services (medical care and physi- 
cian contact with caregivers) that  may affect the 
course of AD. 
We had an  opportunity to  assess the effect of par- 
ticipation in clinical trials in a cohort of patients 
with AD. AD patients followed in a natural history 
study of disease course were offered a n  opportunity 
to participate in controlled RCTs in the first 2 years 
of follow-up. About half the patients participated in 
at least one of the RCTs for some period of time. At 
the same time, information was available for all sub- 
jects in the cohort, allowing us to determine retro- 
spectively which patients may have been eligible for 
the study but did not participate and which patients 
were ineligible. We then compared outcomes over an  
additional 1.5 years, for a total maximal follow-up of 
3.5 years, among patients who participated in the 
RCTs (i.e., the group of patients receiving drug or 
placebo), patients who were eligible for the trials but 
did not participate, and patients who were ineligible. 
The comparison of central interest is whether time to 
reach AD milestones differs between RCT partici- 
pants and nonparticipants who were eligible to par- 
ticipate. 
Methods. Subjects. Subjects in this research come from 
the Predictor’s a multisite longitudinal study of 
patients with AD. Beginning in 1988, patients were re- 
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cruited into the cohort from Columbia University, Johns 
Hopkins University, and Massachusetts General Hospital. 
Patients were enrolled from memory disorders clinics and 
neurology practices, and received detailed clinical evalua- 
tions every 6 months. To be included in the cohort, pa- 
tients had to  meet DSM-111-R criteria for dementing dis- 
ease along with National Institute of Neurological 
Disorders and Stroke (N1NDS)-Alzheimer’s Disease and 
Related Disorders Association (ADRDA) criteria for proba- 
ble AD. In addition, subjects were recruited to be at  a 
relatively mild stage of dementia, defined as a modified 
Mini-Mental State Examination (MMSE) score of 230,‘j 
corresponding to approximately 16 on the standard 
MMSE. The cohort enrolled 236 patients, who have been 
followed for as long as 6 years. Enrollment of the cohort 
and baseline features have been des~r ibed .~ .~  Because 
nursing home placement is an outcome of interest for this 
research, we limited analyses to  the 215 subjects who were 
living in the community at baseline. 
In the first 2 years of follow-up, subjects in the cohort 
could have participated in a variety of clinical trials con- 
ducted at the different study sites. Agents included phy- 
sostigmine, piracetram, and acetyl carnitine, although a 
small number of subjects was recruited for other RCTs as 
well. Patients spent varying amounts of time in clinical 
trials and may have participated in more than one trial. 
Patients were considered to be participants 
in a clinical trial if they were enrolled in a clinical trial at 
any point in the first 2 years of follow-up, as indicated by 
clinical trial status at the first five study assessments (at 
baseline, and at 6, 12, 18, and 24 months). A score was 
calculated to indicate the proportion of time subjects were 
involved in trials, taking into account deaths and loss to  
follow-up. Because of the small numbers of subjects in any 
given trial, and because of our interest in examining the 
effect of RCT participation itself, we did not attempt anal- 
yses of particular RCTs. Site effects were assessed by 
introducing a term for recruitment site in multivariate 
models. 
Nonparticipants in the RCTs were divided into two 
groups-an eligible, nonparticipant group and an ineligible 
group- based on inclusion-exclusion criteria for the RCTs, 
which were uniform across the different clinical trials. The 
ineligible group included subjects who met any of the fol- 
lowing exclusion criteria: not living with an informant, 
currently taking a psychoactive medication, and presence 
of life-threatening condition (e.g., active cancer). Subjects 
who did not participate in any of the RCTs and who did not 
meet exclusion criteria were considered eligible nonpartic- 
ipants. 
Outcomes were assessed over 3.5 years of follow-up, 
including the initial 2-year period, because not all subjects 
have completed subsequent follow-up assessments. The 
following end points were examined: mortality (divided by 
primary cause into infectious and chronic disease catego- 
ries), onset of severe functional deficit (defined as a need 
for help in two of three basic activities of daily living 
[ADLs]: dressing, grooming, t~ileting),~ and nursing home 
placement. In addition, two indicators of medical utiliza- 
tion were noted: hospital admissions and physician exami- 
nations conducted as part of routine Predictor’s Study 
follow-up that were triggered by caregiver reports of new 
medical conditions in cohort subjects. For the latter we 
Measures. 
calculated the proportion of subjects who had any hospital- 
ization and the number of medical examinations linked to 
an incident medical condition over the follow-up period. 
Covariates examined in this research include sociode- 
mographic indicators (age at study entry, gender, years of 
schooling) as well as indicators of baseline functioning (in- 
strumental activities of daily living [IADLs] and ADLS),~,~ 
cognitive status,6 agitation, and depres~ion.~ 
Participants in the RCTs, eligible 
nonparticipants, and ineligible subjects were compared at 
baseline using ANOVA to determine comparability of the 
three groups. Post hoc pairwise comparisons were also con- 
ducted using the Scheffe test. Outcomes in the three 
groups were compared first using ANOVA and then using 
survival models to compare time to onset for each end 
point. For these analyses, Kaplan-Meier plots were gener- 
ated for univariate analyses and Cox proportional hazards 
models were generated for multivariate models.lOJ1 Attri- 
tion rates in the three groups were compared to ensure 
that loss to follow-up was not differential across the 
groups. The multivariate models estimate the risk associ- 
ated with RCT status, adjusting for baseline differences 
between the groups. Differences in the proportion hospital- 
ized and those receiving physician workups for incident 
medical conditions were compared using the Chi-square 
test. Differences in patient functional status a t  the time of 
nursing home placement were also examined. 
Statistical Methods. 
Results. Of the 236 subjects enrolled in the cohort, 215 
resided in the community at baseline. Ninety-five were 
enrolled at  Columbia, 76 at  Johns Hopkins, and 44 at  
Massachusetts General Hospital. At 6 months, 177 were 
seen; at 12 months, 173; at 18 months, 155; and at 24 
months, 142. Following the 2-year clinical trial period, 131 
subjects were followed at 30 months, 105 at 36 months, 
and 70 at 42 months. 
Of the 215 subjects residing in the community at base- 
line, 101 participated in a t  least one RCT, 57 met eligibil- 
ity requirements but did not participate, and 57 were inel- 
igible to  participate in the trials. The majority of subjects 
participating in the randomized trials were recruited for 
physostigmine or acetyl carnitine trials. 
Table 1 compares the three groups using one-way 
ANOVA for continuous measures and the Chi-square test 
for proportions. Subjects participating in clinical trials 
were significantly more likely to be male, younger, and 
better educated. In post hoc tests of pairwise differences 
between the groups, subjects recruited for the clinical tri- 
als were significantly younger and better educated than 
eligible subjects who did not participate in the trials ( p  < 
0.01, by Scheffe test for both comparisons). However, the 
three groups did not differ significantly on any measure of 
dementia severity, including measures of function (ADLs), 
cognition, presence of agitation, or  depression. Although 
not shown in table 1, subjects in the three groups also did 
not differ significantly in composite measures of dementia 
severity. For example, at baseline, similar proportions of 
subjects were mildly and moderately demented using the 
Clinical Dementia Rating (CDR) scale.12 In all groups, 
about 90% of subjects were mildly demented at  baseline 
(CDR 1). The medical status of subjects was also similar 
except in the case of neoplastic disease. Ineligible subjects 
were significantly more likely to have had a history of 
cancer (13% versus 0% in both ineligible and eligible non- 
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Table 1 Baseline features of randomized clinical trial participants, eligible nonparticipants, and ineligible subjects 
~ __ _ _ _ ~ _ _ _ _ ~  _ _ _ . ~ ~ . .  ________._______ 
Baseline features Ineligible (N = 57) Elisble nonparticipant (N = 57) On protocol (N = 101) FIX2 
- . _ _ _ _ _ ~ _ _ _ _ . . ~ _ ~ ~ . ~ _ _ _ _ _ _ _ _ . _ _ _ _ _ _ _ _  ~. 
Sociodemographics 
Female (’36) 70.2 59.6 48.5 7.2* 
Age (yr) 75.1 (t 6.3) 73.5 (+  6.9) 69.0 ( 2  8.2) 14.1t 
Education (yr) 12.0 ( 2  3.2) 13.1 ( 2  3.7) 13.9 (Z 3.9) 5.5$ 
Functional status (k 2 SE) 
Blessed IADLS 3.0 t 1.3 3.0 2 1.3 2.8 2 1.2 0.83 
Blessed ADL3 0.58 2 0.84 0.49 2 1.0 0.47 2 0.83 0.30 
mMMS¶ 37.6 2 5.3 38.1 2 6.3 37.9 t 5.5 0.12 
Depression# 3.5 5 4.4 3.7 2 3.8 3.2 2 4.1 0.22 
Agitation (c/o)”” 39.3 36.8 43.6 0.37 
.- ~ ~ _ _ _ ~ _ _ _ _ _ ~  
‘!‘p < 0.05. 
: p  < 0.001. 
rfp < 0.01. 
$ High scores indicate poorer function. 
¶ Range, 0-57. 
# Hamilton 21-item scale. 
** Assessed with single dichotomous item. 
IADL = instrumental activities of daily living; tu>L = activities of daily living; mMMS = modified Mini-Mental State Examination. 
participating groups). The groups did not differ in the 
prevalence of cardiac disease, hypertension, diabetes, psy- 
chiatric disorders, or other conditions elicited by physical 
examination or medical history. 
Ineligible and eligible nonparticipating groups differed 
from RCT participants in the number of assessments com- 
pleted. Over the 2-year clinical trial period, 42.1% and 
47.4% of the ineligible and eligible nonparticipants were 
seen at all five assessments (baseline, and 6, 12, 18, and 24 
months), compared with 63.4% among RCT participants 
( p  < 0.01). Similarly, across the entire 3.5 years of follow- 
up, mean days of follow-up significantly differed between 
the groups: 815.4 days among the ineligibles, 919.7 days 
among eligible nonparticipants, and 1,067.0 days among 
participants in the trials ( p  < 0.05). 
Table 2 compares the three Assessment of outcomes. 
Table 2 Outcomes by clinical trial status (unadjusted) 
groups on outcomes over the 3.5 years of follow-up. The 
mortality experience of the groups did not differ, with 
somewhat more than 25% of patients dying in all three 
groups. A further breakdown by cause of death also did not 
reveal differences. Using death certificate information and 
reports from institutional or family caregivers (when avail- 
able), we divided deaths into infectious disease (e.g., pneu- 
monia) and chronic disease (e.g., cancer) categories. The 
three groups did not differ on either outcome. 
Incidence of severe functional disability, defined as de- 
pendence in two of three basic ADLs (dressing, grooming, 
toileting), also did not differ significantly between the 
groups. 
Among the medical utilization outcomes, neither risk of 
hospitalization (which ranged from 2% to 7%) nor the pro- 
portion receiving more than two physician examinations in 
Outcome Ineligible (N  = 57) Elisble nonparticipant (N = 57) On protocol (N = 101) FIX2 
~. ___ .~ _ _ _ _ _ _ _ _ _ _ _ _ _  - - - __ 
Mortality 
All causes (‘ir) 28.1 24.6 26.7 0.18 
Infectious cause (%) 8.8 5.3 16.8 5.4 
Chronic condition ( %  ) 12.3 10.5 5.9 2.1 
Onset of severe ADL deficit (C t:!: 28.3 48.9 36.5 4.3 
Function 
Medical utilization 
Hospitalization (%)+ 5.3 7.0 2.0 2.5 
Medical examinations (‘;i I +  52.6 50.8 45.5 0.86 
Nursing home admission (‘3 J 31.6 36.8 16.8 8.83 
-- ~ ~ ~ _ _ _ - . .  ~ . ~______ 
*: Deficit in a t  least two of three activities of daily living (ADLs): dressing, grooming, toileting. 
+ Percent greater than or equal to one hospitalization in follow-up period. 
$ Percent greater than or equal to two examinations in follow-up period. 
8 p  < 0.01. 
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Figure 1. Proportion of patients entering a nursing home, by RCT status. 
the follow-up period (which ranged from 46% to 53%) dif- 
fered significantly by participation status. Risk of nursing 
home placement, however, was significantly lower among 
RCT participants. Among RCT participants, 16.8% entered 
nursing homes in the 3.5 years of follow-up compared with 
36.8% among eligible nonparticipants and 31.6% among 
ineligible subjects. Risk of nursing home placement among 
the three groups is presented in figure 1, which shows time 
to nursing home admission, using Kaplan-Meier plots, for 
the three groups. The figure shows that the distribution of 
time to nursing home placement does not differ between 
ineligible and eligible nonparticipants, and that both differ 
significantly from the nursing home placement experience 
of subjects participating in clinical trials ( p  < 0.01). In Cox 
proportional hazards models, in which the baseline covari- 
ates of age, gender, education, and functional status were 
introduced (Blessed ADL and IADL scores), participants in 
clinical trials had a significantly lower risk of nursing 
home entry compared with eligible nonparticipants (rela- 
tive risk, 0.39; 95% CI, 0.19 to  0.79). 
An alternative approach to examining the protective 
effect of clinical trial participation for risk of nursing home 
placement can be seen in figure 2, in which level of partic- 
ipation in the clinical trials is stratified according to the 
proportion of time subjects participated in the trials. Sub- 
jects could have participated in the trials for more than 
half their assessments in the first 2 years of follow-up (N = 
59), for less than half their assessments (N = 401, or not at  
all (the combined group of eligible nonparticipants and 
ineligible subjects). Kaplan-Meier plots for comparison of 
Time in RCT 
A 50%+ 
Time to Nursing Home Placement (Days) 
Figure 2. Proportion of patients entering a nursing home, by length of RCT participation. 
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time to nursing home placement show a dose-response re- 
lationship, with longer time in the clinical trials associated 
with lower risk of nursing home placement ( p  < 0.001 
overall). Subjects participating in trials for more than 5 0 4  
of their assessments had a lower risk of nursing home 
placement than other RCT participants; this difference ap- 
proached statistical significance ( p = 0.06). 
Relation between nursing home placement and patient 
functional deficit among RCT participants and eligible 
nonparticipants. To examine differences in nursing home 
placement in more detail, we compared rates of nursing 
home placement among RCT participants and eligible non- 
participants when subjects reached two well-defined levels 
of incident functional deficit: (1) need for constant supervi- 
sion and (2) severe ADL deficit (defined as the need for 
help in at least two of three ADLs}.' Patients in the eligible 
nonparticipant group were more likely to be placed in 
nursing homes at  early levels of functional dependency. 
For example, of subjects who began to need constant su- 
pervision over the course of the study (an early depen- 
dency milestone), risk of nursing home placement was sig- 
nificantly higher among eligible nonparticipants compared 
with RCT participants (50% versus 21%, p < 0.01). A sim- 
ilar risk difference was seen for subjects reaching the more 
severe dependency end point (654  versus 37%, p < 0.05). 
Discussion. In this cohort of patients with AD, 
clinical trial participation was associated with only 
one difference in outcome over 3.5 years-a signifi- 
cantly lower risk of nursing home placement. The 
association between clinical trial participation and 
reduced risk of nursing home placement was evident 
in multivariate models that adjusted for differences 
in baseline covariates. Notably, RCT participants 
had a lower risk of nursing home placement com- 
pared with a group that was determined to be eligi- 
ble for the trials but did not participate. Thus, it is 
reasonable t o  attribute the difference in nursing 
home placement to some feature linked to participa- 
tion in the trials. 
A number of explanations for this finding are pos- 
sible. One is a true long-term benefit of the thera- 
peutic agents themselves. Knopman et  al.I3 recently 
reported such a benefit for tacrine treatment in AD. 
In 2 years of follow-up, they found that AD patients 
who received doses of tacrine >80 mg per day and 
remained on the medication had a lower risk of nurs- 
ing home placement than patients who discontinued 
the drug or continued on lower doses. The lower rel- 
ative risk of nursing home placement they report is 
comparable with that seen here. However, the ta- 
crine study reported significantly reduced mortality 
as well, which we did not find. Recent randomized 
placebo-controlled trials involving acetyl-L-carnitine 
(ALCAR) and physostigmine salicylate have also 
shown benefits to  AD patients-to early-onset pa- 
tients in the case of &CAR and to patients who 
responded to  the initial-dose titration study period in 
the case of physc~stigmine.'~.'~ Thus there is evidence 
for the efficacy of the therapies used by the RCT 
assessed in this research. However, the RCT group 
in this research included subjects on drug and pla- 
42 NEUROLOGY 49 July 1997 
cebo, because our primary goal was to  assess the 
effect of RCT participation itself. The RCT group also 
included patients on a variety of medications, in 
some cases more than one, taken for variable lengths 
of time. Given the design of this research, we cannot 
rule out the favorable effect of long-term use of med- 
ications in a subset of patients. It is notable, how- 
ever, that subjects who participated in the RCTs for 
longer lengths of time (>50% of study visits) had a 
reduced risk of nursing home placement when com- 
pared with subjects who participated in the RCTs for 
a shorter length of time (see figure 2). Since patients 
in the RCTs were offered long-term, open-label use of 
medications, this may point to a drug effect on re- 
duced nursing home placement. 
A second explanation that might account for the 
difference in outcome is a selection effect. Subjects in 
the eligible nonparticipant group were more likely to 
be placed in nursing homes than subjects in the RCT 
group, even when patients had equivalent levels of 
ADL dependency. Here again a number of explana- 
tions are possible. These patients may have had ad- 
ditional, unmeasured comorbidities that increased 
their risk for placement, although the groups did not 
show such differences at baseline. While we do not 
know if caregivers actually declined participation, 
decisions to decline participation in a clinical trial 
may indicate lower caregiver motivation (or different 
family constellations) and greater likelihood to place 
demented elders in nursing homes. Data on care- 
giving burden and satisfaction,16 necessary to clarify 
this issue, are unavailable for the cohort. 
Finally, a third explanation is the beneficial effect 
of RCT participation itself. Contact with a medical 
service in RCTs may have a beneficial effect of care- 
givers, perhaps enabling them to care for elders at  
home more effectively and in this way to delay nurs- 
ing home placement until later stages of disease. An 
effect of this type might be examined with a study of 
caregiver coping strategies and patterns of service 
use. One would hypothesize that caregivers to  RCT 
participants are better able to cope with the stress of 
caregiving and that they develop such skills through 
contact with service providers. A recent randomized 
trial reported by Mittelman et al.I7 showed that con- 
tact with a comprehensive support and counseling 
service significantly reduced the risk of nursing 
home placement for both mildly and moderately de- 
mented AD patients. 
We conclude that RCT participation in a cohort of 
AD patients may be associated with a reduced risk of 
nursing home placement. Whether this effect is 
linked to long-term drug benefits to  patients, selec- 
tion factors, or a beneficial effect on caregivers re- 
mains unclear. To understand better the benefits of 
RCT participation to AD patients, especially in trials 
that specify nursing home placement as an end 
point, a more systematic evaluation of caregivers 
would seem appropriate, including information on 
caregiver burden, the distribution of caregiving tasks 
among family members (with close attention to type 
of caregiver), attitudes toward nursing home place- 
ment, and the nature of contact with clinical trial 
medical staff. Also, these results suggest that histor- 
ical or other kinds of unrandomized controls may not 
be appropriate as a comparison group in clinical tri- 
als involving AD. Finally, these results favor further 
research to examine how patients participating in 
RCTs may differ from those who do not, both in 
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